Complementation of a capsule deficient Cryptococcus neoformans with Cap64 restores virulence in a murine lung infection

American Journal of Respiratory Cell and Molecular Biology

Volumn 26, Issue 3, 2002, Pages 306-314

  Wilder, Julie A ^a   Olson, Gwyneth K ^a   Chang, Yun C ^a   Kwon Chung, Kyung J ^a   Lipscomb, Mary F ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; FILOBASIDIELLA NEOFORMANS; MURINAE;

FUNGAL PROTEIN;

ANIMAL; ARTICLE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FUNGAL GENE; GENE EXPRESSION REGULATION; GENETIC TRANSFORMATION; GENETICS; IMMUNOLOGY; LUNG MYCOSIS; MICROBIOLOGY; MOUSE; PATHOGENICITY; T LYMPHOCYTE; VIRULENCE;

ANIMALS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; GENES, FUNGAL; LUNG DISEASES, FUNGAL; MICE; T-LYMPHOCYTES; TRANSFORMATION, GENETIC; VIRULENCE;

EID: 0036008405     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/ajrcmb.26.3.4479     Document Type: Article

References (40)

1. Cryptococcus neoformans
2. Virulence factors
3. What makes Cryptococcus neoformans a pathogen?
4. Cryptococcus neoformans. I. Nonencapsulated mutants
5. Susceptibility of congenitally immunodeficient mice to a nonencapsulated strain of Cryptococcus neoformans
6. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence
7. The second capsule gene of Cryptococcus neoformans, CAP64, is essential for virulence
8. T cell-mediated immunity in the lung: A Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice
9. Genetic and phenotypic characterization of capsule mutants of Cryptococcus neoformans
10. Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene
11. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans
12. Nitric oxide: Biochemistry, pathophysiology, and detection
13. A role for gamma interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans
14. Ig heavy chain complex-linked genes influence the immune response in a murine cryptococcal infection
15. Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice
16. Cryptococcal meningitis in the acquired immunodeficiency syndrome
17. Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils
18. Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast
19. Activated neutrophils exhibit enhanced phagocytosis of Cryptococcus neoformans opsonized with normal human serum
20. Factors influencing killing of Crytococcus neoformans by human leukocytes in vitro
21. Role for C5 and neutrophils in the pulmonary intravascular clearance of circulating Cryptococcus neoformans
22. Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion
23. The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages
24. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils
25. Complement depletion in cryptococcal sepsis
26. Active immunization against Crytococcus neoformans
27. Immune response to Cryptococcus neoformans soluble polysaccharide: Immunological unresponsiveness
28. Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique
29. Cellular charge of Cryptococcus neoformans: Contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding
30. Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses
31. Regulation of cell-mediated immunity in cryptococcosis: I. Induction of specific afferent T suppressor cells by cryptococcal antigen
32. Regulation of cell-mediated immunity in cryptococcosis: II. Characterization of first-order T suppressor cells (Ts1) and induction of second-order suppressor cells
33. Regulation of cell-mediated immunity in cryptococcosis: III. Characterization of second-order T suppressor cells (Ts2)
34. Influence of cryptococcal antigens on cell-mediated immunity
35. Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells
36. IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice
37. Macrophage inflammatory protein-1alpha (MIP-lalpha) is required for the efferent phase of pulmonary cell-mediated immunity to a Cryptococcus neoformans infection
38. Non-encapsulated variant of Cryptococcus neofomans: I. Virulence studies and characterization of soluble polysaccharide
39. Phenotypic and functional characterization of human lymphocytes activated by interleukin-2 to directly inhibit growth of Cryptococcus neoformans in vitro
40. Direct interactions of human lymphocytes with the yeast-like organism, Cryptococcus neoformans